FRAGMINE

Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant.

It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of and about 90% of the material within the range of 2000-9000.

LMWHs have a more predictable response, a greater bioavailability, and a longer anti-Xa half life than unfractionated heparin.

Dalteparin can also be safely used in most pregnant women.

Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.

Dalteparin is used as a prophylaxis for deep-vein thrombosis and pulmonary embolisms in patients undergoing general surgery (e.g., abdominal, gynecologic, urologic), and in patients with acute medical conditions (e.g. cancer, bed rest, heart failure, severe lung disease).

It is also used in patients who have severely restricted mobility, which poses a risk for thromboembolic complications.

Dalteparin is also used concomitantly with aspirin and/or other therapy (e.g., nitrates, β-adrenergic blockers, clopidogrel, platelet glycoprotein IIb/IIIa-receptor inhibitors) to reduce the risk of acute cardiac ischemic events.

The patients who undergo this treatment combination have unstable angina or non-ST-segment elevation/non-Q-wave myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes).

It is also used in the prevention of clotting during hemodialysis and hemofiltration in connection with acute renal failure or chronic renal insufficiency.

Dalteparin has an antithrombin binding site that is essential for high affinity binding to the plasma protein antithrombin (ATIII).

Anti-Xa activity of plasma is used as both as an estimate of clotting activity, and as a basis to determine dosage.

Its use should be avoided in patients with a creatinine clearance less than 20 mL/min. In these patients, unfractionated heparin should only be used.

As for monitoring, active partial thromboplastin time (aPTT) will only increase at high doses of low molecular weight heparins (LMWH).

Therefore, monitoring aPTT is not recommended.

However, anti-Xa activity can be measured to monitor the efficacy of the LMWH.

Antithrombin-III Potentiator Vascular endothelial growth factor

A, long form Inhibitor.

Almost completely absorbed after subcutaneous (Subcutaneous) doses, with a bioavialability of about 87%.

Liver and the reticulo-endothelial system are the sites of biotransformation.

They are partially metabolized by desulphatation and depolymerization.

After 4 hours, about 20% is seen in urine.

Most of the remainder is found in the liver, gastrointestinal tract and kidney.

The kidneys are the major site of dalteparin excretion (approximately 70% based on animal studies).

Terminal Half life

Excreted via kidneys.

The plasma clearance rate is 33 mL/min.

Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.

hemorrhagic complications.

Reaction: (common) osteopenia with extended use; mild, reversible non-immunological thrombocytopenia; transient elevation of liver transaminases; alopecia.